Q1. Could you start by giving us a brief overview of your professional background, particularly focusing on your expertise in the industry?

I've spent over 20 years building and scaling pharmaceutical businesses across some of the most complex markets in the world.

I started in Europe, then Middle East and Africa, later Emerging Markets. Eventually ended up leading commercial transformation across more than 80 countries from Singapore. That role taught me something important: execution discipline is what separates a good strategy from an actual result.

For the past several years, I've been based in the Dubai, running a business across five Gulf markets: UAE, Saudi Arabia, Kuwait, Bahrain, and Oman. Full P&L responsibility, roughly 70 people across commercial, medical, and marketing. When I took over, the business was at $120 million. We grew it to $170 million in four years while improving profitability at the same time.

What makes the Gulf genuinely interesting is the complexity underneath the surface. You have government procurement sitting next to private insurance. Distributor models that differ by country. Price regulation that moves without much warning. Tender cycles that can shift your forecast overnight. It sharpens you quickly.

I've launched brands, managed portfolio rationalisation, redesigned distributor partnerships, and built teams from scratch. Across three very different commercial cultures, the constant has always been the same: the quality of the team and the honesty of the execution process determines everything. That's the lens I bring to these questions.

 

Q2. In the Gulf’s General Medicines sector, we see a trend of rising volumes but tightening price caps. From a market-wide perspective, what is the reason and key drivers for this margin expansion seen by top players?

This is a question I find myself having almost every quarter, and the honest answer is that it's rarely one thing.

From what I've seen on the ground, the top players expanding margin in this environment are doing two things simultaneously.

First, they optimize their portfolio mix. The days of depending on a broad generics-adjacent basket to drive revenue are fading. The companies doing well are leaning into differentiated brands, either specialty products, vaccines or established medicines with genuine clinical differentiation, where price caps bite less and patient outcomes justify the premium. If you're still anchoring your business on commoditised molecules, the math stops working eventually.

Second, and this is less talked about, is the tender channel. Volume wins in government procurement, even at compressed prices, create something valuable: scale. When you win a national tender, your supply chain, your distribution, your field engagement costs all get absorbed across a much larger base. The per-unit economics improve even if the headline price drops.

Third, omnichannel transformation. Digital only approach in promotion, account management are much more efficient than boots on the ground. That being said, they work for some brands in certain market dynamics - and not much for others.

What I'd caution against is assuming this is sustainable without active portfolio management. Tightening price caps are a structural reality in this part of the world, not a temporary inconvenience. The companies that will look good in five years are the ones reinvesting margin into pipeline access now, not coasting on yesterday's mix.

 

Q3. The UAE recently shifted from an 'exclusive' to a 'multi-agent' distribution model for certain portfolios. From a market perspective, is this successfully increasing product availability?

The short answer is: it depends - on how you define "working."

It’s there as legislation but not yet fully implemented. It comes with its own set of challenges and opportunities. The big test will be whether your agents are competing on service quality, account coverage, speed of delivery, cold chain management, or just splitting the same customer base between them and creating internal channel conflict.

The transition also has the risk of creating short-term noise. Inventory gets fragmented. Forecasting gets harder. Some customers get double-visited while others fall through the gaps.

My read is that the shift is directionally right for the market, but the execution burden will largely land on manufacturers. The companies that will benefit most will be those who invested in distributor governance, clear KPIs, joint business plans, regular reviews, before the model changed, not after.

 

Q4. To what extent are the strengthening localization mandates across the Gulf clusters impacting the OpEx-to-Revenue ratios of international firms? Can digital transformation fully offset the rising costs of local talent acquisition?

Moderate is the honest answer, but "moderate" has a wide range depending on how prepared you were.

The pressure is real. Emiratisation in UAE, Saudisation in KSA: these are not soft guidelines anymore. There are targets, there are fees for non-compliance, and there is genuine regulatory scrutiny. For international firms used to deploying global talent as they see fit, that requires a genuine rethink of workforce planning.

Where it stings most is at the mid-management level. Senior local talent, people who can genuinely run a function, is limited and expensive. You end up in a competitive market with other multinationals for a small pool of qualified candidates. Salaries inflate. Retention becomes a real cost. And if you're structuring roles purely to hit a headcount target rather than building genuine capability, you create drag, not value.

Can digital transformation offset this? Partially. I've seen AI-powered tools reduce the need for certain roles: content generation, data analysis, even parts of field force productivity that used to require large teams. But technology solves efficiency problems. It doesn't solve the talent strategy problem.

The companies managing this well planned their localization roadmap two to three years ahead. They are building pipelines, running development programmes, and gave local talent meaningful roles with real accountability. 

 

Q5. As the Gulf market shifts toward omnichannel engagement, is this technology creating a competitive moat that favors large multinationals, or is it lowering the 'cost-to-entry' for regional generic players to reach physicians at a lower price point? What are your thoughts on this?

Both, depending on which part of omnichannel you're talking about.

The infrastructure layer, the CRM platforms, the data architecture, the consent management systems, the analytics capability, that absolutely favours large multinationals. The upfront investment is significant. I've been part of deployments across 80-plus countries, and the complexity of getting a clean, compliant, integrated system working at scale is not something a regional generics player can replicate cheaply or quickly. That part is a moat.

But the content and reach layer is a different story. A regional generics company with a focused portfolio and a clear message can now reach a doctor on a tablet, via email, through a third-party medical platform, at a fraction of what it cost five years ago. The channels themselves have become more accessible. What used to require a full field force can now be done with a leaner digital-first model. 

So the real question is what you're trying to build. If the goal is deep, personalised, data-driven engagement at the individual physician level, the kind that builds genuine advocacy for a complex brand, the multinationals have a structural advantage. If the goal is awareness and basic reach for an established molecule, the cost to entry has genuinely dropped.

The risk for large companies is assuming that having the infrastructure means you're winning. I've seen very sophisticated platforms with very low adoption from reps and very low engagement from doctors. Technology without behaviour change is just expensive software.

 

Q6. As Saudi and UAE payers move toward 'Value-Based Reimbursement' (paying for outcomes rather than pills), how are pharmaceutical firms refactoring their commercial teams to move from 'volume-selling' to 'health-economic partnership'?

I want to be direct here because I think the industry does itself a disservice by overstating how far along this shift actually is. The frameworks are being discussed at payer level in Saudi Arabia and the UAE. Health technology assessment processes are maturing. Formulary decisions are increasingly asking for real-world evidence rather than just clinical trial data. That is genuine progress.

But inside most commercial teams? The incentive structures, the call objectives, the sales force metrics: they still largely reward volume. Reps are still measured on prescriptions, not patient outcomes. Key account managers are still navigating formulary access with reimbursement arguments built around cost per pill, not cost per quality-adjusted outcome. The language has changed. The behaviour mostly hasn't.

What I've seen in the teams that are genuinely trying to move is a real skills gap. Selling on volume is a learned behaviour reinforced over years. Health economics partnership requires a completely different conversation, with a different stakeholder, in a different room, using a different evidence base. That takes more than training. It takes structural redesign: different roles, different profiles, different KPIs.

The companies that will be well-positioned in five years are already building those capabilities now, even if the payer system hasn't fully caught up. The ones waiting for the market to force the change will find themselves without the talent or the evidence packages to compete when it does.

 

Q7. If you were an investor looking at companies within the space, what critical question would you pose to their senior management?

I'd ask two things, blended into one conversation.

First: "Strip out your tender wins from the last two years. What does your organic private market growth actually look like?" Tender volume can make a business look healthy from the outside when the underlying commercial engine is barely moving. 

Second: "What's the one market or product where your strategy isn't working right now, and what are you doing about it?" This one is less about the answer and more about how they respond. A team that can name it clearly, explain why, and tell you exactly what they're changing, that's a team that actually runs the business. A team that gets vague or pivots straight to the wins, that tells you something too.

In certain geographies, growth numbers can look impressive at the headline level. The market itself is expanding. You can ride that wave for a while without being genuinely good at what you do.

What I want to know is whether the business is built on real commercial capability or on favourable conditions. Because conditions change.     

Those two questions, asked together, usually tell you which one you're looking at.